US9192750B2ExpiredUtilityA1
Method and device for controlling drug pharmacokinetics
Est. expiryMay 6, 2022(expired)· nominal 20-yr term from priority
A61M 37/0015A61M 2037/0023A61M 2037/0061A61M 5/3291
70
PatentIndex Score
4
Cited by
148
References
7
Claims
Abstract
Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.
Claims
exact text as granted — not AI-modifiedThat which is claimed:
1. A method for delivering insulin to a subject comprising utilizing at least one delivery device to deliver insulin to the subject, wherein insulin is delivered to both the intradermal and the subcutaneous compartments, wherein the delivery device comprises a single needle or cannula, wherein the single needle or cannula comprises a side port that delivers insulin into the intradermal compartment, and wherein the single needle or cannula further comprises an end port that delivers insulin into the subcutaneous compartment, wherein the end port inserts into the subject's skin at a depth of at least about 2.0 mm to about 5.0 mm.
2. The method of claim 1 , wherein delivery of insulin into the intradermal and subcutaneous compartments is essentially simultaneous.
3. The method of claim 1 , wherein delivery of insulin into the intradermal and subcutaneous compartments is using algorithms having logic components that include physiologic models, rules based models or moving average methods, therapy pharmacokinetic models, monitoring signal processing algorithms, predictive control models, or combinations thereof.
4. The method of claim 1 , wherein delivery of insulin into the intradermal and subcutaneous compartments is by a bolus injection.
5. The method of claim 1 , wherein delivery of insulin into the intradermal and subcutaneous compartments is by a metered bolus injection.
6. The method of claim 1 , wherein delivery of insulin into the intradermal and subcutaneous compartments is by an infusion.
7. The method of claim 1 , wherein delivery of insulin into the intradermal and subcutaneous compartments is at a dose of 100-200μl.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.